Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting
@article{Oo2005DrugIN, title={Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting}, author={T. Oo and P. Hesketh}, journal={Nature Clinical Practice Oncology}, year={2005}, volume={2}, pages={196-201} }
Nausea and vomiting remain among the most feared side effects of chemotherapy for cancer patients. Significant progress has been made in the last 15 years in developing more effective and better-tolerated measures to minimize chemotherapy-induced nausea and vomiting (CINV). During the 1990s, the selective 5-hydroxytryptamine receptor antagonists were first introduced for the treatment of CINV, and resulted in more effective and better tolerated treatment of CINV. Despite recent progress… CONTINUE READING
36 Citations
Palonosetron Hydrochloride in the Treatment of Chemotherapy-Induced Nausea and Vomiting
- Medicine
- 2009
- 2
Novel neurokinin-1 antagonists as antiemetics for the treatment of chemotherapy-induced emesis.
- Medicine
- Supportive cancer therapy
- 2006
- 22
Effect of Hydroxyzine in Controlling Acute Chemotherapy-Induced Vomiting in Children: A Randomised Trial
- Medicine
- 2012
- 3
- PDF
NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.
- Medicine
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- 2020
The cost of antiemetic therapy for chemotherapy-induced nausea and vomiting in patients receiving platinum-containing regimens in daily practice in Japan: a retrospective study
- Medicine
- Supportive Care in Cancer
- 2011
- 10
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2011
- 181
Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study
- Medicine
- Supportive Care in Cancer
- 2009
- 138
A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients.
- Medicine
- Molecular and clinical oncology
- 2016
- 13
- PDF
References
SHOWING 1-10 OF 18 REFERENCES
Treatment of chemotherapy-induced emesis in the 1990s: impact of the 5-HT3 receptor antagonists
- Medicine
- Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
- 1994
- 52
Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting
- Medicine
- Supportive Care in Cancer
- 2000
- 42
Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting
- Medicine
- Cancer investigation
- 2000
- 136
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2003
- 425
Effect of aprepitant for the prevention of nausea and vomiting after one cycle of moderately emetogenic chemotherapy: A randomized double-blind trial in 866 patients.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2004
- 15
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2004
- 141
Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
- Medicine
- Supportive Care in Cancer
- 2004
- 97
- PDF
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
- Medicine
- European journal of cancer
- 2004
- 145
The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2003
- 699